1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70, 7–30. https://doi.org/10.3322/caac.21590 (2020).
2. Stromnes, I. M., DelGiorno, K. E., Greenberg, P. D. & Hingorani, S. R. Stromal reengineering to treat pancreas cancer. Carcinogenesis 35, 1451–1460. https://doi.org/10.1093/carcin/bgu115 (2014).
3. Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817–1825. https://doi. org/10.1056/NEJMoa1011923 (2011).
4. Mizrahi, J. D., Surana, R., Valle, J. W. & Shrof, R. T. Pancreatic cancer. Lancet 395, 2008–2020. https://doi.org/10.1016/s0140- 6736(20)30974-0 (2020).
5. Kinzler, K. W. et al. Identifcation of FAP locus genes from chromosome 5q21. Science 253, 661–665. https://doi.org/10.1126/scien ce.1651562 (1991).
6. Friend, S. H. et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323, 643–646. https://doi.org/10.1038/323643a0 (1986).
7. Antony, J., Zanini, E., Birtley, J. R., Gabra, H. & Recchi, C. Emerging roles for the GPI-anchored tumor suppressor OPCML in cancers. Cancer Gene Ter. 28, 18–26. https://doi.org/10.1038/s41417-020-0187-6 (2021).
8. Chaufaille, M., Zalcberg, I., Barreto, W. G. & Bendit, I. Detection of somatic TP53 mutations and 17p deletions in patients with chronic lymphocytic leukemia: a review of the current methods. Hematol. Transfus Cell Ter. 42, 261–268. https://doi.org/10. 1016/j.htct.2020.05.005 (2020).
9. Calhoun, E. S. et al. Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays. Cancer Res. 66, 7920–7928. https://doi.org/10.1158/0008-5472.Can-06-0721 (2006).
10. Qiu, W. et al. Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo. Oncotarget 2, 862–873. https://doi.org/10.18632/oncotarget.357 (2011).
11. Alimov, A. et al. Combined LOH/CGH analysis proves the existence of interstitial 3p deletions in renal cell carcinoma. Oncogene 19, 1392–1399. https://doi.org/10.1038/sj.onc.1203449 (2000).
12. Partridge, M., Emilion, G. & Langdon, J. D. LOH at 3p correlates with a poor survival in oral squamous cell carcinoma. Br. J. Cancer 73, 366–371. https://doi.org/10.1038/bjc.1996.62 (1996).
13. Zabarovsky, E. R., Lerman, M. I. & Minna, J. D. Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene 21, 6915–6935. https://doi.org/10.1038/sj.onc.1205835 (2002).
14. Counter, C. M. et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 11, 1921–1929 (1992).
15. Meyerson, M. et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90, 785–795. https://doi.org/10.1016/s0092-8674(00)80538-3 (1997).
16. Low, K. C. & Tergaonkar, V. Telomerase: Central regulator of all of the hallmarks of cancer. Trends Biochem. Sci. 38, 426–434. https://doi.org/10.1016/j.tibs.2013.07.001 (2013).
17. Hannen, R. & Bartsch, J. W. Essential roles of telomerase reverse transcriptase hTERT in cancer stemness and metastasis. FEBS Lett. 592, 2023–2031. https://doi.org/10.1002/1873-3468.13084 (2018).
18. Liu, Z. et al. Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells. Oncogene 32, 4203–4213. https://doi.org/10.1038/onc.2012.441 (2013).
19. Collins, K. & Mitchell, J. R. Telomerase in the human organism. Oncogene 21, 564–579. https://doi.org/10.1038/sj.onc.1205083 (2002).
20. Abe, S. et al. Localization of an hTERT repressor region on human chromosome 3p21.3 using chromosome engineering. Genome Integr. 1, 6. https://doi.org/10.1186/2041-9414-1-6 (2010).
21. Nishio, S. et al. Repression of hTERT transcription by the introduction of chromosome 3 into human oral squamous cell carcinoma. Biochem. Biophys. Res. Commun. 466, 755–759. https://doi.org/10.1016/j.bbrc.2015.09.119 (2015).
22. Yuan, X., Larsson, C. & Xu, D. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: Old actors and new players. Oncogene 38, 6172–6183. https://doi.org/10.1038/s41388-019-0872-9 (2019).
23. Qi, D. L. et al. Identifcation of PITX1 as a TERT suppressor gene located on human chromosome 5. Mol Cell Biol 31, 1624–1636. https://doi.org/10.1128/mcb.00470-10 (2011).
24. La, S. H., Kim, S. J., Kang, H. G., Lee, H. W. & Chun, K. H. Ablation of human telomerase reverse transcriptase (hTERT) induces cellular senescence in gastric cancer through a galectin-3 dependent mechanism. Oncotarget 7, 57117–57130. https://doi.org/10. 18632/oncotarget.10986 (2016).
25. Hata, T. et al. Simple detection of telomere fusions in pancreatic cancer, intraductal papillary mucinous neoplasm, and pancreatic cyst fuid. J. Mol. Diagn. 20, 46–55. https://doi.org/10.1016/j.jmoldx.2017.09.006 (2018).
26. Dratwa, M., Wysoczańska, B., Łacina, P., Kubik, T. & Bogunia-Kubik, K. TERT-regulation and roles in cancer formation. Front. Immunol. 11, 589929. https://doi.org/10.3389/fmmu.2020.589929 (2020).
27. Killela, P. J. et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc. Natl. Acad. Sci. USA 110, 6021–6026. https://doi.org/10.1073/pnas.1303607110 (2013).
28. Koorstra, J. B., Hustinx, S. R., Oferhaus, G. J. & Maitra, A. Pancreatic carcinogenesis. Pancreatology 8, 110–125. https://doi.org/ 10.1159/000123838 (2008).
29. van Heek, N. T. et al. Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am. J. Pathol. 161, 1541–1547. https://doi.org/10.1016/s0002-9440(10)64432-x (2002).
30. Matsuda, Y. et al. Gradual telomere shortening and increasing chromosomal instability among PanIN grades and normal ductal epithelia with and without cancer in the pancreas. PLoS ONE 10, e0117575. https://doi.org/10.1371/journal.pone.0117575 (2015).
31. Grant, T. J., Hua, K. & Singh, A. Molecular pathogenesis of pancreatic cancer. Prog. Mol. Biol. Transl. Sci. 144, 241–275. https:// doi.org/10.1016/bs.pmbts.2016.09.008 (2016).
32. Zakov, S., Kinsella, M. & Bafna, V. An algorithmic approach for breakage-fusion-bridge detection in tumor genomes. Proc. Natl. Acad. Sci. USA 110, 5546–5551. https://doi.org/10.1073/pnas.1220977110 (2013).
33. Hong, S. M. et al. Telomeres are shortened in acinar-to-ductal metaplasia lesions associated with pancreatic intraepithelial neoplasia but not in isolated acinar-to-ductal metaplasias. Mod. Pathol. 24, 256–266. https://doi.org/10.1038/modpathol.2010.181 (2011).
34. Gomes, N. M. et al. Comparative biology of mammalian telomeres: Hypotheses on ancestral states and the roles of telomeres in longevity determination. Aging Cell 10, 761–768. https://doi.org/10.1111/j.1474-9726.2011.00718.x (2011).
35. Guterres, A. N. & Villanueva, J. Targeting telomerase for cancer therapy. Oncogene 39, 5811–5824. https://doi.org/10.1038/s41388- 020-01405-w (2020).
36. Chiappori, A. A. et al. A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer. Ann. Oncol. 26, 354–362. https://doi.org/10.1093/annonc/mdu550 (2015).
37. Hesson, L. B., Cooper, W. N. & Latif, F. Evaluation of the 3p21.3 tumour-suppressor gene cluster. Oncogene 26, 7283–7301. https:// doi.org/10.1038/sj.onc.1210547 (2007).
38. Sharp, T. V. et al. Te chromosome 3p213-encoded gene, LIMD1, is a critical tumor suppressor involved in human lung cancer development. Proc. Natl. Acad. Sci. USA 105, 19932–19937. https://doi.org/10.1073/pnas.0805003105 (2008).
39. Wang, K., Ling, T., Wu, H. & Zhang, J. Screening of candidate tumor-suppressor genes in 3p21.3 and investigation of the methylation of gene promoters in oral squamous cell carcinoma. Oncol. Rep. 29, 1175–1182. https://doi.org/10.3892/or.2012.2213 (2013).
40. Dammann, R. et al. Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma. Oncogene 22, 3806–3812. https://doi.org/10.1038/sj.onc.1206582 (2003).
41. Amato, E. et al. RASSF1 tumor suppressor gene in pancreatic ductal adenocarcinoma: Correlation of expression, chromosomal status and epigenetic changes. BMC Cancer 16, 11. https://doi.org/10.1186/s12885-016-2048-0 (2016).
42. Tanaka, H., Horikawa, I., Barrett, J. C. & Oshimura, M. Evidence for inactivation of distinct telomerase repressor genes in diferent types of human cancers. Int. J. Cancer 115, 653–657. https://doi.org/10.1002/ijc.20879 (2005).
43. Liu, Y. et al. Deletions linked to TP53 loss drive cancer through p53-independent mechanisms. Nature 531, 471–475. https://doi. org/10.1038/nature17157 (2016).
44. Ohira, T. et al. PITX1 protein interacts with ZCCHC10 to regulate hTERT mRNA transcription. PLoS ONE 14, e0217605. https:// doi.org/10.1371/journal.pone.0217605 (2019).
45. Kugoh, H., Ohira, T. & Oshimura, M. Studies of tumor suppressor genes via chromosome engineering. Cancers https://doi.org/ 10.3390/cancers8010004 (2015).
46. Kugoh, H., Shigenami, K., Funaki, K., Barrett, J. C. & Oshimura, M. Human chromosome 5 carries a putative telomerase repressor gene. Genes Chromosomes Cancer 36, 37–47. https://doi.org/10.1002/gcc.10135 (2003).